The existence in human plasma of a corticosteroid-binding protein was described by Daughaday in 19561 and given the name "transcortin" by Slaunwhite and Sandberg.2 Since then, transcortin has been the subject of extensive investigation,3-12 and several reviews summarize the properties and function of this protein.13-21 The concentration of transcortin in serum or plasma may be determined indirectly through its corticosteroid-binding properties by equilibrium dialysis,5 by measuring the in vitro distribution of C14-cortisol between plasma and red blood cells,22 or by gel filtration.23,30 It has been shown that transcortin has a high affinity for cortisol, so that when the plasma cortisol concentration is approximately 20μg to 30μg per 100 ml, the binding sites of this protein are virtually saturated.11 Seal and Doe have described a method for the isolation and purification of transcortin from normal plasma and from plasma of diethylstilbesterol-treated
BEIER FR, LAHEY ME, HEINER DC. Serum Transcortin Levels in Acute Leukemia. Am J Dis Child. 1963;106(4):381–387. doi:10.1001/archpedi.1963.02080050383007
Customize your JAMA Network experience by selecting one or more topics from the list below.